Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis

References

• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi:10.1007/s12016-018-8702-3
   PubMed Web of Science ®Google Scholar
• Bagel J, Tatla D, Hellot S, et al. Bimekizumab self-injection devices: two multicenter, randomized, open-label studies on self-administration by patients with psoriasis. J Drugs Dermatol. 2022;21(2):162–171. doi:10.36849/JDD.6274
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486. doi:10.1016/S0140-6736(21)00126-4
   PubMed Web of Science ®Google Scholar
• Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279–1288. doi:10.1001/jamadermatol.2021.2905
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomized controlled trials. Ann Rheum Dis. 2023;82(4):515–526. doi:10.1136/ard-2022-223595
   PubMed Web of Science ®Google Scholar
• Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48. doi:10.1016/S0140-6736(22)02303-0
   PubMed Web of Science ®Google Scholar
• McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25–37. doi:10.1016/S0140-6736(22)02302-9
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):130–141. doi:10.1056/NEJMoa2102388
   PubMed Web of Science ®Google Scholar
• Borrás-Blasco J, Gracia-Pérez A, Dolores Rosique-Robles J, et al. Acceptability of switching Adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10(3):301–307. doi:10.1517/14712590903530633
   PubMed Web of Science ®Google Scholar
• Borrás-Blasco J, Gracia-Pérez A, Casterá MD, et al. Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen. Expert Opin Biol Ther. 2013;13(8):1103–1108. doi:10.1517/14712598.2013.795942
   PubMed Web of Science ®Google Scholar
• Tornero Molina J, López Robledillo JC, Casamira Ruiz N. Potential benefits of the self-administration of subcutaneous methotrexate with autoinjector devices for patients: a review. Drug Healthc Patient Saf. 2021;13:81–94. doi:10.2147/DHPS.S290771
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med. 2017;17(1):65–70. doi:10.7861/clinmedicine.17-1-65
   PubMed Web of Science ®Google Scholar
• Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423–441. doi:10.1007/s40265-014-0191-y
   PubMed Web of Science ®Google Scholar
• Jevtic V, Lingg G. Differential diagnosis of rheumatoid and psoriatic arthritis at an early stage in the small hand and foot joints using magnetic resonance imaging. Handchir Mikrochir Plast Chir. 2012;44(03):163–170. doi:10.1055/s-0032-1321760
   PubMedGoogle Scholar
• Candiri B, Talu B, Demirtas Karaoba D, Ozaltin GE, Yolbas S. Effect of psoriatic arthritis on the strength, proprioception, skill, coordination, and functional condition of the hand. Int J Rheum Dis. 2022;25(1):47–55. doi:10.1111/1756-185X.14241
   PubMed Web of Science ®Google Scholar
• Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the self-injection assessment questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(1):2. doi:10.1186/1477-7525-9-2
   PubMed Web of Science ®Google Scholar
• UCB Biopharma SRL. A study to assess the long-term safety, tolerability, and efficacy of bimekizumab in the treatment of subjects with active psoriatic arthritis (BE VITAL). NLM identifier: NCT04009499. Available from: https://clinicaltrials.gov/ct2/show/NCT04009499. Accessed June 21, 2023.
   Google Scholar
• Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS Pain), numeric rating scale for pain (NRS Pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res. 2011;63(Suppl 11):S240–S252.
   PubMed Web of Science ®Google Scholar
• Gau M, Takasawa K. Initial patient choice of a growth hormone device improves child and adolescent adherence to and therapeutic effects of growth hormone replacement therapy. J Pediatr Endocrinol Metab. 2017;30(9):989–993. doi:10.1515/jpem-2017-0146
   PubMed Web of Science ®Google Scholar